IHC of MiTF on an FFPE Melanoma Tissue
|For In Vitro Diagnostic Use
|Summary and Explanation
|Microphthalmia-associated Transcription Factor (MiTF) is a basic helix-loop-helix leucine zipper transcription factor involved in melanocyte and osteoclast development. Mutations in MiTF cause auditory pigmentary syndromes, such as Waardenburg Syndrome Type II, Type IIa and Tietz Syndrome in humans. There are two known isoforms of MiTF differing by 66 amino acids at the NH2 terminus. Shorter forms are expressed in melanocytes and run as two bands at 52 kDa and 56 kDa, while the longer Mi form runs as a cluster of bands at 60-70 kDa in osteoclasts and in B16 Melonoma cells (but not other Melanoma cell lines), as well as mast cells and heart cells. MiTF plays a critical role in the differentiation of various cell types such as neural crest-derived melanocytes, mast cells, osteoclasts and optic cup-derived retinal pigment epithelium. This antibody recognizes serine phosphorylated and non-phosphorylated melanocytic isoforms of microphthalmia. It is useful in identifying Malignant Melanoma, and distinguishing mast cell lesions from lesions of myeloid derivation. A relatively rare class of tumors known as PEComas (tumors showing perivascular epithelioid cell differentiation) express MiTF in a high percentage of cases (~90%).
|Anti-MiTF is cocktail of two mouse monoclonal antibodies derived from cell culture supernatant that are concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.
|Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product.